Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone

References

• Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434–1443.
   PubMed Web of Science ®Google Scholar
• Camaschella C, Silvestri L. New and old players in the hepcidin pathway. Comment on Haematologica. 2008;93(10):1473–1479.
   PubMed Web of Science ®Google Scholar
• Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat.Genet. 2014;46(7):678–684.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271–1276.
   PubMed Web of Science ®Google Scholar
• Ganz T, Olbina T, Girelli G, et al. Immunoassay for human hepcidin. Blood. 2008;112:4292–4297.
   PubMed Web of Science ®Google Scholar
• Maes K, Nemeth E, Roodman GD, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010;116(18):3635–3644.
   PubMed Web of Science ®Google Scholar
• Tanno T, Rabel A, Alleyne M, et al. Hepcidin, anaemia, and prostate cancer. BJU Int. 2011;107:678–679.
   PubMed Web of Science ®Google Scholar
• Kamai T, Tomosugi N, Abe H, et al. Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer. 2009;9:270.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Weingart O, Trelle S, et al. Cancer-related anemia and recombinant human erythropoietin–an updated overview. Nat Clin Pract Oncol. 2006;3:152–164.
   PubMedGoogle Scholar
• Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093.
   PubMed Web of Science ®Google Scholar
• Orlandi R, De Bortoli M, Ciniselli CM, et al. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann Oncol. 2014;25(2):352–357.
   PubMed Web of Science ®Google Scholar
• Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116(Suppl. 7A):11S–26S.
   PubMed Web of Science ®Google Scholar
• Durigova A, Lamy PJ, Thezenas S, et al. Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification. Clin Chem Lab Med. 2013;51:1833–1841.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer. 2001;91:2214–2221.
   PubMed Web of Science ®Google Scholar
• Troutt JS, Rudling M, Persson L, et al. Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration. Clin Chem. 2012;58:1225–1232.
   PubMed Web of Science ®Google Scholar
• Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011;117:e218–25.
   PubMed Web of Science ®Google Scholar
• Thomas DW, Hinchliffe RF, Briggs C, et al. British Committee for Standards in Haematology. Guideline for the Laboratory Diagnosis of Functional iron Deficiency. Br J Haematol. 2013;161:639–648.
   PubMed Web of Science ®Google Scholar
• Enko D, Wagner H, Kriegshäuser G, et al. Hepcidin-25 vs. conventional clinical biomarkers in the diagnosis of functional iron deficiency iron deficiency. Br J Haematol. 2013;161:639–648.
   PubMed Web of Science ®Google Scholar
• D’Auria L, Bonifati C, Mussi A, et al. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumor necrosis factor-alfa levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw. 1997;8:383–387.
   PubMed Web of Science ®Google Scholar
• Hollander M, Wolfe DA. Nonparametric statistical methods. 2nd ed. New York: John Wiley & Sons; 1999.
   Google Scholar
• Artusi R, Verderio P, Marubini E. Bravais-Pearson and Spearman correlation coefficients: meaning, test of hypothesis and confidence interval. Int J Biol Markers. 2002;17:148–151.
   PubMed Web of Science ®Google Scholar
• Shu T, Jing C, Lv Z, et al. Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis. Eur J Haematol. 2015;94(1):67–73.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large multinational, prospective survey defining prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293–2306.
   PubMed Web of Science ®Google Scholar
• Macciò A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica. 2015;100:124–132.
   PubMed Web of Science ®Google Scholar
• Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumour progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999;19:1427–1432.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461–2463.
   PubMed Web of Science ®Google Scholar
• Hepcidin GT. a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783–788.
   PubMed Web of Science ®Google Scholar
• McCranor BJ, Kim MJ, Cruz NM, et al. Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells. Blood Cells Mol Dis. 2014;52(2–3):126–133.
   PubMed Web of Science ®Google Scholar
• Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat. 2007;102:129–135.
   PubMed Web of Science ®Google Scholar
• Salgado R, Junius S, Benoy I, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103:642–646.
   PubMed Web of Science ®Google Scholar
• Casanovas G, Mleczko-Sanecka K, Altamura S, et al. Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. J Mol Med. 2009;87(5):471–480.
   PubMed Web of Science ®Google Scholar
• Alarmo EL, Kallioniemi A. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? Endocr Relat Cancer. 2010;17(2):R123–39.
   PubMed Web of Science ®Google Scholar
• Van Houten EL, Laven JS, Louwers YV, et al. Bone morphogenetic proteins and the polycystic ovary syndrome. J Ovarian Res. 2013;6(1):32.
   PubMed Web of Science ®Google Scholar